Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients (NCT02359123) | Clinical Trial Compass
CompletedNot Applicable
Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients
Israel24 participantsStarted 2016-11
Plain-language summary
The main purpose in the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) is to prolong life and to improve quality of life (QoL) as far as possible. QoL in patients with CACS is directly related to loss of appetite and loss of weight. Cannabis pills are given in Israel to advanced cancer patients with various symptoms in order to improve their QoL. There is data on safety/toxicity of cannabis, and these pills are given under the regulations of the Israel Ministry of Health.
The purpose of this study is to examine the influence of Cannabics capsules on improving loss of appetite and loss of weight.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age above 18 years
. Histological evidence of an incurable malignancy
. Estimated life expectancy ≥3 months
. Performance status ≤2 (ECOG classification)
. Self-report of weight loss of at least 3kg during the preceding 2 months and/or a dietitian-estimated caloric intake of less than 20 calories/kg of body weight per day
. Patient believes that loss of appetite or loss of weight is an ongoing problem for him
. Use of chemotherapy or radiotherapy is permitted
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
weight gain of ≥10% from baseline weight assessed.
. Ongoing use of tube feedings or parental nutrition
. Edema or ascites
. Central nervous system metastases or brain tumors (patients with stable disease in the brain 28 days after treatment can be included in the study)
. Treatment with adrenal corticosteroids (except for short-term dexamethasone during time of chemotherapy), androgens, progestational agents or other appetite stimulants within the previous two weeks
. Insulin-requiring diabetes
. Pregnancy or lactation or unwillingness to use oral contraceptives
. Other life-threatening medical conditions
. Anticipated alcohol or barbiturate use during the study period